Business - Briefly   

Ranbaxy starts anti-malarial molecule trials

GURGAON: Ranbaxy Laboratories on Monday commenced Phase-III clinical trials for its new anti-malaria combination drug, Arterolane maleate + Piperaquine phosphate in India, Bangladesh and Thailand. The drug is targeted at patients in developing countries with the aim of significantly improving the conventional options available for the treatment of P. falciparum malaria, according to a release.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Benchmark index surges by over 700 points
Maruti expects higher sales
HDFC net profit dips
Nalco alumina production hit
OVL to invest $1.45 b in Iraq
Marginal increase in IOB’s net profit
United India posts 14 % rise in premium income
Exchange Rates
Bullion Rates
Ranbaxy starts anti-malarial molecule trials
Study on property and asset management
iSOFT wins hospital info system deal
Covidien sets up centre in Gurgaon
GEEC commissions second pipeline

Copyright © 2009, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu